Stock listing

KRX:475830 Orum Therapeutics, Inc. (오름테라퓨틱) 주가

Follow Orum Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · KRX:475830

₩16,240 KRW -940 (-5.5%)

Close on Oct 20, 2026

Past year -53.7% · daily closes, Oct 20, 2025 – Oct 20, 2026, adjusted for splits
Day range
₩16,130 – ₩17,230 KRWOct 20, 2026
Volume
122,400 sharesOct 20, 2026
Market cap
₩352.7B KRWAt the close on Oct 20, 2026 · price × 21.72M shares outstanding
52-week range
₩15,690 – ₩146,600 KRWLowest and highest trades, Oct 21, 2025 – Oct 20, 2026
Orum Therapeutics, Inc. logo

Daily closes

Last 3 months, Jul 20, 2026 – Oct 20, 2026 · KRX:475830 · KRW, adjusted for splits

DayCloseChange%OpenHighLowVolume
₩16,240-940-5.5%₩17,000₩17,230₩16,130122,400
₩17,180+380+2.3%₩16,570₩17,250₩16,160115,064
₩16,800+780+4.9%₩16,500₩17,400₩16,100193,290
₩16,020-1,690-9.5%₩16,500₩16,830₩15,690213,731
₩17,710+690+4.1%₩17,630₩18,410₩17,280271,494
₩17,020-800-4.5%₩17,000₩17,490₩16,490238,499
₩17,820-1,450-7.5%₩18,890₩19,000₩17,770291,359
₩19,270-1,330-6.5%₩20,000₩20,100₩19,190355,101
₩20,600+150+0.7%₩20,700₩20,900₩20,200248,354
₩20,450-700-3.3%₩20,950₩21,300₩20,150395,065
₩21,150-2,200-9.4%₩23,200₩23,550₩20,950541,140
₩23,350+1,200+5.4%₩21,850₩23,900₩21,500385,381
₩22,150-350-1.6%₩22,300₩23,150₩21,650371,322
₩22,500-1,750-7.2%₩23,600₩23,600₩20,850713,857
₩24,250-750-3.0%₩25,750₩26,000₩24,100375,622
₩25,000-400-1.6%₩25,550₩26,450₩24,800666,525
₩25,400-1,900-7.0%₩27,100₩27,100₩24,4501,450,215
₩27,300-10,100-27.0%₩26,450₩29,050₩26,2004,887,210
₩37,400-16,000-30.0%₩37,400₩37,400₩37,40033,235
₩53,400+2,700+5.3%₩51,700₩53,500₩51,00091,901
₩50,700+200+0.4%₩49,500₩51,100₩48,40038,617
₩50,500+550+1.1%₩50,500₩52,800₩49,75069,010
₩49,950-1,050-2.1%₩49,400₩50,700₩48,25066,517
₩51,000-2,100-4.0%₩50,700₩52,000₩49,50071,516
₩53,100-700-1.3%₩52,100₩53,600₩51,100115,375
₩53,800+800+1.5%₩53,000₩55,400₩52,60063,732
₩53,000-1,100-2.0%₩53,600₩54,900₩52,90048,444
₩54,100-1,800-3.2%₩55,600₩56,300₩53,50098,357
₩55,900+1,400+2.6%₩55,900₩57,000₩53,20083,639
₩54,500-1,800-3.2%₩57,200₩57,900₩53,70079,197
₩56,300-2,900-4.9%₩57,500₩59,600₩55,300175,157
₩59,200-5,800-8.9%₩63,500₩64,100₩58,500151,982
₩65,000-1,000-1.5%₩62,600₩66,000₩59,600136,530
₩66,000-800-1.2%₩66,700₩67,500₩63,90060,446
₩66,800-1,400-2.1%₩67,100₩68,900₩65,50074,330
₩68,200-2,500-3.5%₩70,700₩72,800₩68,20082,186
₩70,700-1,800-2.5%₩70,900₩71,700₩66,500113,681
₩72,500+10,500+16.9%₩63,700₩74,300₩63,700290,962
₩62,000-9,700-13.5%₩68,100₩69,000₩62,000140,313
₩71,700+1,400+2.0%₩73,400₩74,100₩67,900167,970
₩70,300+4,600+7.0%₩64,500₩72,000₩63,100250,537
₩65,700-2,400-3.5%₩66,000₩68,700₩64,200124,095
₩68,100+1,200+1.8%₩66,600₩69,300₩65,50086,569
₩66,900+1,000+1.5%₩65,200₩68,300₩63,60071,835
₩65,900-5,100-7.2%₩69,900₩70,200₩63,800188,949
₩71,000+1,100+1.6%₩69,200₩75,700₩68,000219,770
₩69,900+8,000+12.9%₩63,300₩72,800₩62,900256,584
₩61,900+3,400+5.8%₩58,000₩62,200₩56,800132,083
₩58,500-500-0.8%₩58,500₩60,800₩54,800101,810
₩59,000+1,100+1.9%₩57,700₩60,000₩56,700159,215
₩57,900+9,450+19.5%₩48,050₩58,400₩48,050310,331
₩48,450+3,850+8.6%₩42,650₩50,200₩42,400123,818
₩44,600+6,800+18.0%₩39,550₩45,700₩39,000122,891
₩37,800-1,750-4.4%₩36,100₩40,900₩36,10093,131
₩39,550-4,200-9.6%₩44,750₩44,750₩36,750180,436
₩43,750-3,700-7.8%₩45,650₩47,000₩40,35068,757
₩47,450+1,950+4.3%₩46,600₩49,600₩45,30081,231
₩45,500-2,200-4.6%₩46,050₩48,900₩45,25081,763
₩47,700+5,250+12.4%₩42,450₩48,100₩42,250102,461
₩42,450+550+1.3%₩42,200₩44,950₩41,70071,340
₩41,900-100-0.2%₩41,300₩42,400₩39,25096,300
₩42,000-3,400-7.5%₩44,100₩44,200₩41,25072,015
Ticker
KRX:475830
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
KRX
Currency
KRW

What changed lately

Latest news

Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate

Aug 23, 2026

Closed ₩72,500 (+16.9%) on Aug 24, 2026

Orum Therapeutics Appoints Dr. Maria Koehler and Geoff Meyerson to Board of Directors

Apr 13, 2026

Closed ₩86,300 (+0.7%) on Apr 14, 2026

Orum Therapeutics to Present New Preclinical Data on ORM-1153, a CD123-Targeting Degrader Antibody Conjugate, at the AACR Annual Meeting 2026

Mar 17, 2026

Closed ₩129,600 (+6.7%) on Mar 18, 2026

Orum Therapeutics Announces Presentation of Preclinical Data for ORM-1153 at the 2025 American Society of Hematology (ASH) Annual Meeting

Nov 3, 2025

Closed ₩52,000 (+4.5%) on Nov 4, 2025

Orum Therapeutics Appoints Dr. Dorin Toader as Head of Platform Technology to Advance Orum’s Degrader–Antibody Conjugate Payload Platforms and Expand TPD²® Therapeutic Applications

Oct 14, 2025

All Orum Therapeutics, Inc. news

Decks

Orum Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
4 in the last 12 months · 5 in all · newest Aug 23, 2026 · oldest 2025
Decks
2 decks · latest 2026

Log in to ask 6ix AI your own questions about Orum Therapeutics, Inc.